AMPLIMED RECEIVES ORPHAN-DRUG DESIGNATION FOR AMPLIMEXON

AmpliMed has announced that its lead drug Amplimexon has been granted orphan-drug designation for the treatment of ovarian cancer by the FDA.

Preclinical studies have indicated that Amplimexon is effective at killing ovarian cancer cells in doses that can be achieved following administration of the drug to humans. In addition, the drug has been shown to act synergistically with other drugs commonly used to treat ovarian cancer, such as taxotere and platinum-containing anticancer drugs.